Quick Answer
Mineralys Therapeutics, Inc. reported Total Assets of $661.81 million for fiscal year 2025.
Mineralys Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $661.81M | +221.4% |
| 2024 | $205.90M | -18.2% |
| 2023 | $251.64M | +119.9% |
| 2022 | $114.44M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $599.95M | +123.6% | +78.7% |
| June 30, 2025 | $335.72M | +5.4% | -5.4% |
| March 31, 2025 | $354.94M | +2.2% | +72.4% |
| December 31, 2024 | $205.90M | -18.2% | -23.2% |
| September 30, 2024 | $268.25M | -3.4% | -15.8% |
| June 30, 2024 | $318.49M | +9.4% | -8.3% |
| March 31, 2024 | $347.25M | +13.3% | +38.0% |
| December 31, 2023 | $251.64M | +119.9% | -9.3% |
- Mineralys Therapeutics, Inc. showed an increase of +221.4% in Total Assets compared to the prior fiscal year.
- Over the 2022–2025 period, Mineralys Therapeutics, Inc.’s total assets has grown by 478.3% (from $114.44 million to $661.81 million).
- The most recent figure is from Mineralys Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: